News | Tomotherapy | May 19, 2020

Accuray Synchrony Wins 2020 MedTech Breakthrough Award

Annual awards program recognizes outstanding health and medical technology products and companies

May 19, 2020 — Accuray Incorporated announced that MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, has selected the Accuray Synchrony Real-time Adaptive Technology for the Radixact System as the winner of its "Best Overall Medical Device Solution" award in the fourth annual MedTech Breakthrough Awards program.

The Radixact System, the next-generation TomoTherapy platform, is a radiotherapy system designed to provide oncology clinical teams with the imaging capabilities, treatment flexibility and precise dose delivery they had come to expect with its predecessor device, with the addition of components that can significantly enhance interoperability and increase patient throughput.

Originally developed to expand on the Accuray CyberKnife System's unique automatic motion tracking and synchronization capabilities, Synchrony for the Radixact System is designed to adapt for tumors that move as a result of bodily processes, including respiration and digestion, as well as patient movement. Some tumors may be located in areas of the body that move regularly, such as the lungs. Also, filling of the bladder, gas in the bowel or even slight patient movements can shift the tumor target by a millimeter or more.

Tracking tumor movement — and synchronizing precise treatment delivery with that movement using the Accuray Synchrony Real-time Adaptive Technology — helps to maximize treatment effectiveness and minimize dose to surrounding tissues. The beams of radiation are delivered continuously throughout the treatment session as the patient breathes naturally. In comparison, gating methods deliver radiation only when the tumor is close to the expected location and pause treatment delivery when the moving tumor is outside of the "treatment window." This lengthens the time the patient needs to be on the treatment table.

"Cancer is increasingly being managed as a chronic condition. With this will be a corresponding rise in the use of radiation therapy, and a need for technology that can precisely and accurately treat each patient's unique tumor," said Joshua H. Levine, president and CEO at Accuray. "Our one-of-a-kind, artificial-intelligence driven Synchrony software combined with the Radixact System delivers a breakthrough in precision radiation therapy treatments. Synchrony is the only technology that uses image guidance to automatically adapt and synchronize the radiation beam to the position of the tumor if and when it moves during treatment. When used with the Radixact System, it facilitates the efficient and effective delivery of both hypofractionated and standard radiation therapy, making it easier for clinical teams to provide treatments tailored to meet each individual patient's needs."

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year's program attracted more than 3,750 nominations from over 15 different countries throughout the world.

"The Synchrony Real-time Adaptive Technology for the Radixact System embodies the spirit of the MedTech Breakthrough Awards program by delivering a true breakthrough for cancer patients and the clinicians who treat them," said James Johnson, managing director, MedTech Breakthrough. "Accuray has developed a powerful portfolio of advanced technology solutions that is revolutionizing radiation therapies for patients, minimizing the amount of healthy tissue exposed to high-dose radiation and, ultimately, helping to improve patient outcomes. We are thrilled to award Accuray with the marquee "Best Overall Medical Device Solution" designation for their breakthrough technology that is strengthening and advancing the toolkit for cancer-fighting solutions. Congratulations to the entire Accuray team on their well-deserved industry recognition with this 2020 MedTech Breakthrough award."

For more information:

Related Content

Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.